Excessive activation of IL-33/ST2 in cancer-associated fibroblasts promotes invasion and metastasis in ovarian cancer.
IL-33
M2 macrophage
cancer-associated fibroblast
metastasis
ovarian cancer
Journal
Oncology letters
ISSN: 1792-1082
Titre abrégé: Oncol Lett
Pays: Greece
ID NLM: 101531236
Informations de publication
Date de publication:
May 2022
May 2022
Historique:
received:
08
04
2020
accepted:
01
12
2020
entrez:
11
4
2022
pubmed:
12
4
2022
medline:
12
4
2022
Statut:
ppublish
Résumé
Ovarian cancer is highly prevalent and has high mortality rates due to metastasis and relapse. The cross communication between cancer-associated fibroblasts (CAFs) and cancer-associated macrophages (CAMs) in the ovarian tumor microenvironment leads to cancer cell invasion and metastasis. However, the role of overproduction of IL-33/ST2 in the CAFs of ovarian cancer is still unclear. The expression of IL-33, ST2, apoptosis-related proteins and epithelial-mesenchymal transition (EMT) markers was measured by western blotting. Primary normal fibroblasts and CAFs from ovarian cancerous tissue were isolated and cultured
Identifiants
pubmed: 35399326
doi: 10.3892/ol.2022.13278
pii: OL-0-0-13278
pmc: PMC8987947
doi:
Types de publication
Journal Article
Langues
eng
Pagination
158Informations de copyright
Copyright: © Feng et al.
Déclaration de conflit d'intérêts
The authors declare that they have no competing interests.
Références
Gynecol Oncol. 2019 Jun;153(3):589-596
pubmed: 30905436
Oncogene. 2017 Jun 22;36(25):3648-3649
pubmed: 28166198
Oncogene. 2020 Mar;39(12):2539-2549
pubmed: 31988451
J Biomed Nanotechnol. 2018 Oct 1;14(10):1826-1835
pubmed: 30041728
World J Surg Oncol. 2020 Nov 7;18(1):289
pubmed: 33160379
Nat Rev Gastroenterol Hepatol. 2019 May;16(5):282-295
pubmed: 30778141
Mol Ther Nucleic Acids. 2020 Mar 6;19:654-667
pubmed: 31955007
Asian Pac J Cancer Prev. 2019 Dec 01;20(12):3563-3569
pubmed: 31870095
Mol Cancer Res. 2018 Jul;16(7):1196-1204
pubmed: 29636362
Obstet Gynecol. 2019 Feb;133(2):245-254
pubmed: 30633128
J Cancer Res Clin Oncol. 2016 Feb;142(2):437-46
pubmed: 26374424
Am J Pathol. 2020 Jan;190(1):206-221
pubmed: 31610176
Clin Cancer Res. 2016 Aug 15;22(16):4057-66
pubmed: 26994146
Nat Commun. 2016 Oct 11;7:13050
pubmed: 27725631
J Hematol Oncol. 2016 Feb 06;9:8
pubmed: 26851944
Oncol Rep. 2019 Feb;41(2):1045-1050
pubmed: 30535474
Oncogene. 2014 May 8;33(19):2423-31
pubmed: 23728338
Mol Oncol. 2016 Jan;10(1):113-25
pubmed: 26433471
Int J Mol Sci. 2018 Sep 09;19(9):
pubmed: 30205617
Trends Cancer. 2016 Feb;2(2):84-94
pubmed: 28741553
Acta Biomater. 2018 Aug;76:146-153
pubmed: 30078422
Nat Rev Cancer. 2020 Mar;20(3):174-186
pubmed: 31980749
Cancer Lett. 2020 Jul 1;481:63-75
pubmed: 32145343
Genome Biol. 2019 Jan 14;20(1):12
pubmed: 30642385
Cancer Discov. 2019 Feb;9(2):173-175
pubmed: 30737215
Mol Cancer. 2017 Aug 29;16(1):148
pubmed: 28851377
Cancer Cell Int. 2019 Dec 21;19:347
pubmed: 31889899
J Immunother Cancer. 2019 Feb 13;7(1):45
pubmed: 30760333
Int J Cancer. 2019 Apr 1;144(7):1486-1495
pubmed: 30155891